S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.64
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Is CRISPR Therapeutics the NVIDIA of gene editing?
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

$9.08
+0.09 (+1.00%)
(As of 08:38 AM ET)
Today's Range
$9.08
$9.08
50-Day Range
$4.35
$8.99
52-Week Range
$1.06
$9.66
Volume
26,307 shs
Average Volume
5.07 million shs
Market Capitalization
$447.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.88

C4 Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.8% Upside
$9.88 Price Target
Short Interest
Healthy
8.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of C4 Therapeutics in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.28) to ($2.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.49 out of 5 stars

Medical Sector

870th out of 935 stocks

Biological Products, Except Diagnostic Industry

147th out of 157 stocks


CCCC stock logo

About C4 Therapeutics Stock (NASDAQ:CCCC)

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC Stock Price History

CCCC Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
CCCC Mar 2024 8.500 put
CCCC Mar 2024 7.000 put
Reviewing XOMA (NASDAQ:XOMAO) and C4 Therapeutics (NASDAQ:CCCC)
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
C4 Therapeutics price target raised by $1 at Stifel, here's why
C4 Therapeutics Stock (NASDAQ:CCCC) Insider Trades
CCCC Feb 2024 9.000 put
CCCC Feb 2024 4.500 put
Analyst Expectations For C4 Therapeutics's Future
C4 Therapeutics Inc (CCCC)
SRPT Aug 2024 140.000 call
See More Headlines
Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/26/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CCCC
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.88
High Stock Price Target
$20.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+9.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-128,180,000.00
Net Margins
-638.34%
Pretax Margin
-658.12%

Debt

Sales & Book Value

Annual Sales
$20.76 million
Book Value
$5.91 per share

Miscellaneous

Free Float
45,353,000
Market Cap
$443.03 million
Optionable
Optionable
Beta
2.99

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Andrew J. Hirsch M.B.A. (Age 53)
    CEO, President & Director
    Comp: $971k
  • Dr. Kenneth C. Anderson M.D. (Age 73)
    Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $39.03k
  • Dr. Stewart  FisherDr. Stewart Fisher (Age 57)
    Chief Scientific Officer
    Comp: $657.34k
  • Mr. Scott N. Boyle M.B.A. (Age 46)
    Ph.D., Chief Business Officer
    Comp: $672.78k
  • Dr. Nathanael S. Gray Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Kendra Adams
    Chief Financial Officer
  • Mr. Mark Mossler (Age 51)
    Chief Accounting Officer
  • Ms. Jolie M. Siegel J.D. (Age 47)
    Chief Legal Officer & Corporate Secretary
    Comp: $610.4k
  • Ms. Kelly A. Schick (Age 44)
    Chief People Officer
  • Dr. Isabel Chiu Ph.D.
    Senior Vice President of Strategic Alliances & Business Development














CCCC Stock Analysis - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CCCC shares.
View CCCC analyst ratings
or view top-rated stocks.

What is C4 Therapeutics' stock price target for 2024?

6 equities research analysts have issued 12 month target prices for C4 Therapeutics' stock. Their CCCC share price targets range from $2.00 to $20.00. On average, they anticipate the company's share price to reach $9.88 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for CCCC
or view top-rated stocks among Wall Street analysts.

How have CCCC shares performed in 2024?

C4 Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, CCCC stock has increased by 59.1% and is now trading at $8.99.
View the best growth stocks for 2024 here
.

Are investors shorting C4 Therapeutics?

C4 Therapeutics saw a decline in short interest during the month of January. As of January 31st, there was short interest totaling 3,350,000 shares, a decline of 39.6% from the January 15th total of 5,550,000 shares. Based on an average trading volume of 14,290,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 8.7% of the company's shares are short sold.
View C4 Therapeutics' Short Interest
.

When is C4 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CCCC earnings forecast
.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.06. The firm had revenue of $8.50 million for the quarter, compared to analysts' expectations of $7.28 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 55.30% and a negative net margin of 638.34%.

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (14.49%), Commodore Capital LP (7.71%), Price T Rowe Associates Inc. MD (5.19%), Price T Rowe Associates Inc. MD (5.19%), Vanguard Group Inc. (4.06%) and Point72 Asset Management L.P. (3.98%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar.
View institutional ownership trends
.

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CCCC) was last updated on 2/26/2024 by MarketBeat.com Staff